| TheraCIM (nimotuzumab) / Daiichi Sankyo, Oncoscience, Biocon |
ACTRN12610000560099: A Study of Nimotuzumab in Combination With Radiation Therapy in Patients With Brain Metastases from Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 88 | | | YM BioSciences Inc., YM BioSciences Inc. | Non-Small Cell Lung Cancer with brain metastases | | | | |
ACTRN12610000571077: A Phase I-II Clinical Study of Nimotuzumab (TheraCIM h-R3) in Combination with External Radiotherapy in Stage IIB, III and IV Non-Small Cell Lung Cancer (NSCLC) |
|
|
| Recruiting | 2 | 128 | | | YM BioSciences Inc., YM BioSciences Inc. | Non-Small Cell Lung Cancer (NSCLC) | | | | |
ChiCTR-ONC-12002130: Open-Label, Uncontrolled, Multicenter Phase II Study of Cisplatin and 5-Fu Combined With Nimotuzumab As First-Line Treatment in Patients With Untreated Metastatic Nasopharyngeal Carcinoma |
|
|
| Completed | 2 | 39 | | cisplatin+5-Fu+nimotuzumab | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Sponsored by Biotech Pharmaceuticals Co.Ltd. | Metastatic Nasopharyngeal Carcinoma | | | | |
ChiCTR-IIR-16007712: Nimotuzumab (Taixinsheng) combined with radiotherapy and chemotherapy for protecting the laryngeal function of locally advanced hypopharyngeal and laryngeal cancer patients: a multi-center, single-blind, randomized, controlled, phase II study |
|
|
| Recruiting | 2 | 100 | | nimotuzumab (200mg) combine with Radiotherapy and Cisplatin ;nimotuzumab (200mg) combine with Radiotherapy and Docetaxel | People's Liberation Army General Hospital; People's Liberation Army General Hospital, biotech pharmaceutical co.,ltd | Hypopharyngeal cancer, laryngeal cancer | | | | |
ChiCTR-OIC-16008201: Nimotuzumab combined cisplatin, 5-fluorouracil neoadjuvant chemotherapy follow by cisplatin synchronous intensity-modulated radiotherapy in locally advanced nasopharyngeal carcinoma: a multicenter, prospective phase II study |
|
|
| Recruiting | 2 | 60 | | Nimotuzumab combined cisplatin, 5-fluorouracil neoadjuvant chemotherapy | The fourth affiliated hospital of Guangxi Medical University; The fourth affiliated hospital of Guangxi Medical University, Key specialist funds | Locally advanced nasopharyngeal carcinoma | | | | |
NCT03666221: Nimotuzumab for Recurrent Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 67 | RoW | Nimotuzumab, Radiation | Fujian Cancer Hospital, Sun Yat-sen University, Jiangxi Provincial Cancer Hospital, Zhejiang Cancer Hospital, Fujian Medical University Union Hospital | Recurrent Nasopharyngeal Carcinoma | 04/20 | 11/22 | | |
NCT03915132: Nimotuzumab Combined With VMAT in Elderly Patients With Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 47 | RoW | Nimotuzumab, Taixinsheng, VMAT | Chinese Academy of Medical Sciences | Nasopharyngeal Carcinoma | 05/20 | 05/22 | | |
NCT03708822: Study of Docetaxel and Cisplatin Combined With Nimotuzumab As First-Line Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 2 | 48 | RoW | Docetaxel and Cisplatin and Nimotuzumab | Sun Yat-sen University | Nasopharyngeal Carcinoma | 07/22 | 06/24 | | |
NCT04136600: EGFR Monoclonal Antibody for Advanced Gastric Cancer |
|
|
| Recruiting | 2 | 100 | RoW | EGFR antibody and Chemotherapy, Chemotherapy | Shanghai Changzheng Hospital | Gastric Cancer, Cetuximab, Nimotuzumab | 08/21 | 12/21 | | |
NCT04207918: A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer |
|
|
| Completed | 2 | 55 | RoW | Radiotherapy, Nimotuzumab, S-1 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Chemoradiotherapy, Nimotuzumab, Unresectable Malignant Neoplasm | 12/22 | 06/23 | | |
Carpp-1, NCT04882462: Sintilimab and Nimotuzumab Combined With Chemotherapy for the Treatment of R/M HNSCC. |
|
|
| Not yet recruiting | 2 | 100 | NA | Nimotuzumab, Sintilimab, Chemotherapy drug | The First Affiliated Hospital of Soochow University, Biotech Pharmaceutical Co., Ltd., Cinda Biopharmaceutical (Suzhou) Co., Ltd. | Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | 11/21 | 12/22 | | |
NCT04367909: A Study of TC(Docetaxel and Carboplatin) Regimen With or Without Nimotuzumab in Recurrent Metastatic Oral Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 68 | RoW | Nimotuzumab, Docetaxel, Carboplatin | Xin-Hua Xu | Oral Squamous Cell Carcinoma | 12/21 | 12/22 | | |
NCT04833205: Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer |
|
|
| Recruiting | 2 | 30 | RoW | Nimotuzumab, EGFR-TKI | Hui Bu | Leptomeningeal Metastasis, Lung Cancer | 04/22 | 04/23 | | |
NCT06404840: Evaluating Nimotuzumab in Combination With AG Regimen for Pancreatic Cancer With Liver Metastases : A Prospective, Single-Arm, Phase II Study |
|
|
| Recruiting | 2 | 30 | RoW | nimotuzumab, AG chemotherapy | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 03/25 | 05/26 | | |
DIPG, NCT03620032: Study of Re-irradiation at Relapse Versus RT and Multiple Elective rt Courses |
|
|
| Active, not recruiting | 2 | 54 | Europe | Nimotuzumab, humanized therapeutic monoclonal antibody, Vinorelbine, Chemotherapy, Radiotherapy | Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, University of Roma La Sapienza, Johannes Gutenberg University Mainz, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Wuerzburg University Hospital | Diffuse Intrinsic Pontine Glioma | 11/22 | 11/24 | | |
NCT04223024: Concurrent Chemoradiotherapy With Nimotuzumab for High Risk Nasopharyngeal Carcinoma |
|
|
| Active, not recruiting | 2 | 246 | RoW | CCRT+Nimotuzumab, Nimotuzumab, CCRT alone | Sun Yat-sen University | Nasopharyngeal Carcinoma | 12/22 | 12/26 | | |
NCT03766178: Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma |
|
|
| Not yet recruiting | 2 | 45 | RoW | Nimotuzumab + SHR-1210 | The First Affiliated Hospital of Zhengzhou University | Esophageal Squamous Cell Carcinoma | 12/22 | 09/23 | | |
| Recruiting | 2 | 400 | RoW | Avitinib Maleate, AC0010, Afatinib, Giotrif, Crizotinib, Xalkori, X-396, ensartinib, Chidamide, Epidaza, Pyrotinib Maleate, SHR1258, AZD3759, Pirotinib, KBP-5209, Nimotuzumab, Pemetrexed, LY231514, Cisplatin, CDDP, Sintilimab, Gemcitabine, LY188011, Carboplatin, NSC 241240 | Guangdong Association of Clinical Trials, Chinese Thoracic Oncology Group | Carcinoma, Non-Small-Cell Lung | 12/22 | 12/24 | | |
NCT06455072: Nituzumab Plus Serplulimab Combined With SBRT in Cervical Cancer |
|
|
| Recruiting | 2 | 37 | RoW | Nituzumab, monoclonal antibody, Serplulimab, Immune checkpoint inhibitors | Fujian Cancer Hospital, Zhangzhou Municipal Hospital of Fujian Province | Cervical Cancer | 01/25 | 01/25 | | |
NCT06410651: Nimotuzumab Concurrent With Chemoradiotherapy for Patients With Unresectable Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 2 | 53 | RoW | Nimotuzumab with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy | 12/25 | 12/26 | | |
NCT06429839: Nimotuzumab Concurrent With Chemoradiotherapy for Esophageal Cancer Patients |
|
|
| Recruiting | 2 | 55 | RoW | Nimotuzumab with chemoradiotherapy | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Esophageal Cancer, Nimotuzumab, Chemoradiotherapy, Chemotherapy, Immunotherapy | 12/25 | 12/26 | | |
NCT06405685: Nimotuzumab Plus AG in Pancreatic Cancer With Liver Metastasis |
|
|
| Recruiting | 2 | 30 | RoW | Nimotuzumab, h-R3, AG | Tianjin Medical University Cancer Institute and Hospital | Pancreatic Cancer | 10/25 | 10/25 | | |
ChiCTR2000035678: Concurrent nimotuzumab with intensity modulated radiotherapy for locoregionally advanced aged nasopharyngeal carcinoma |
|
|
| Not yet recruiting | 2 | 95 | | Concurrent nimotuzumab with intensity modulated radiotherapy | Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, none | nasopharyngeal carcinoma | | | | |
ChiCTR2100049181: Nimotuzumab plus chemotherapy for unresectable locally advanced or metastatic pancreatic cancer and biliary tract cancer: an open-label, prospective, phase II basket trial |
|
|
| Not yet recruiting | 2 | 16 | | None | Peking University International Hospital; Peking University International Hospital, self-funded | pancreatic cancer and biliary tract cancer | | | | |
NCT06413017: Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure |
|
|
| Recruiting | 2 | 30 | RoW | Nimotuzumab, h-R3, ICIs(Immune checkpoint inhibitors), PD-1 or PD-L1 | Tianjin Medical University Cancer Institute and Hospital | HCC | 07/25 | 12/25 | | |
NCT05508347: Nituzumab (Taixinsheng ®） A Prospective, Randomized, Double-blind, Placebo-controlled, Multicenter Phase II Clinical Study on the Efficacy and Safety of Combined Induction Chemotherapy for Locally Advanced Nasopharyngeal Carcinomatreatment of Locally Advanced Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 170 | RoW | Nituzumab/placebo, Nituzumab injection (taixinsheng) | Sichuan Cancer Hospital and Research Institute | Nasopharyngeal Carcinoma | 09/23 | 09/23 | | |
NCT06389760: Single-arm Study of Nimotuzumab Combined With mFOLFIRNIOX as Postoperative Adjuvant Therapy in Pancreatic Cancer |
|
|
| Recruiting | 2 | 50 | RoW | Nimotuzumab, Taixinsheng, mFOLFIRINOX | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | Pancreatic Cancer | 09/26 | 09/26 | | |
GCR-05, NCT05606263: Efficacy and Safety of Caldonirimab Plus Nimotuzumab for Recurrent or Metastatic Cervical Cancer |
|
|
| Recruiting | 2 | 55 | RoW | Caldonirimab and Nimotuzumab | Health Science Center of Xi'an Jiaotong University | Cervical Cancer | 11/23 | 11/25 | | |
NCT04664244: Combination of Nimotuzumab and Radiotherapy for Recurrent Uterine Cervical Squamous Carcinoma |
|
|
| Recruiting | 2 | 43 | RoW | Combination of nimotuzumab and radiotherapy | Lei Li | Recurrent Cervical Carcinoma, Radiotherapy, Epidermal Growth Factor Receptor, Nimotuzumab, Objective Response Rate, Progression-free Survival, Overall Survival | 12/23 | 12/23 | | |
ChiCTR2100041780: Nimotuzumab combined with PD-1 Sintilizumab in the second-line treatment of advanced esophageal squamous cell carcinoma: a single-arm, open phase II clinical study |
|
|
| Recruiting | 2 | 42 | | Nimotuzumab combined with sintilizumab | The Sixth Medical Center of PLA General Hospital; The Sixth Medical Center of PLA General Hospital, BIOTECH PHARMA | Esophageal Carcioma | | | | |
ChiCTR2100051133: A single-center, single-arm, phase II clinical study of the efficacy and safety of nimotuzumab combined with sintilimab in the treatment of recurrent/metastatic head and neck squamous cell carcinoma |
|
|
| Not yet recruiting | 2 | 41 | | Nimotuzumab combined with Sintilimab | The Fifth Affiliated Hospital of Guangzhou Medical University; The Fifth Affiliated Hospital of Guangzhou Medical University, Enterprise subsidy | squamous cell carcinoma of the head and neck | | | | |
NCT06259721: Anti-PD1 Monoclonal Antibody Combined With Nimotuzumab and Capecitabine in Patients With First-line Platinum-resistant Recurrent/Metastatic Nasopharyngeal Carcinoma |
|
|
| Recruiting | 2 | 22 | RoW | Anti-PD1 antibody, nimotuzumab and capecitabine | Jiangxi Provincial Cancer Hospital | Nasopharyngeal Carcinoma | 02/26 | 08/26 | | |
ChiCTR2200058765: A Phase II study of the safety and efficacy of sintilimab in combination with chemotherapy and Nimotuzumab induction therapy, Nimotuzumab synchronous radiotherapy (IMRT), followed by six months of maintenance therapy with sintilimab in advanced nasopharyngeal carcinoma |
|
|
| Recruiting | 2 | 30 | | sintilimab combined nimotuzumab | The First Affiliated Hospital of Nanchang University; The First Affiliated Hospital of Nanchang University, Innovent Biological Inc (Suzhou) | nasopharyngeal carcinoma | | | | |
NCT06414577: Irinotecan Liposomes in Combination With Nituzumab for the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma After Failure of First-Line or Higher Immunotherapy |
|
|
| Not yet recruiting | 2 | 37 | RoW | Irinotecan Liposomal combined With Nituzumab | XIANG YANQUN | Nasopharyngeal Cancer | 05/25 | 05/26 | | |
NCT06429904: Nimotuzumab Plus NALIRIFOX in Locally Advanced Pancreatic Cancer |
|
|
| Active, not recruiting | 2 | 31 | RoW | Nimotuzumab+ NALIRIFOX | Peking Union Medical College Hospital | Locally Advanced Pancreatic Cancer | 05/27 | 05/27 | | |
ChiCTR2200060564: Nimotuzumab combined with neoadjuvant chemotherapy (TPF) in the treatment of resectable locally advanced head and neck squamous cell carcinoma |
|
|
| Not yet recruiting | 2 | 55 | | Nimotuzumab combined with chemotherapy (PF protocol) | Xijing Hospital of the Air Force Military Medical University; Xijing Hospital of the Air Force Military Medical University, Enterprise funding | Head and neck squamous cell carcinoma | | | | |
NCT05351762: Nimotuzumab Combined With Neoadjuvant Chemotherapy in the Treatment of Resectable LA HNSCC |
|
|
| Not yet recruiting | 2 | 55 | NA | Nimotuzumab Combined With Neoadjuvant Chemotherapy, Albumin Paclitaxel, Nedaplatin, Teggio | Xijing Hospital | Head and Neck Squamous Cell Carcinoma | 05/24 | 07/24 | | |
| Not yet recruiting | 2 | 73 | NA | Stereotactic body radiation, SBRT, Nimotuzumab, h-R3, mono-chemotherapy, chemotherapy | Peking University Third Hospital, Biotech Pharmaceutical Co., Ltd. | Advanced Pancreatic Cancer | 06/26 | 06/26 | | |
NCT05803915: Neoadjuvant Toripalimab Plus Nimotuzumab in Oral Squamous Cell Carcinoma Prior to Radical Therapy |
|
|
| Not yet recruiting | 2 | 57 | RoW | Toripalimab, JS001 | Peking Union Medical College Hospital | Oral Squamous Cell Carcinoma | 09/24 | 03/26 | | |
ChiCTR2100043937: A single-arm, open phase II clinical study to evaluate the efficacy and safety of Nimotuzumab Injection combined with concurrent chemoradiotherapy in elderly patients with locally advanced inoperable esophageal squamous cell carcinoma |
|
|
| Recruiting | 2 | 23 | | Nimotuzumab, Tegafur Gimer and radiotherapy | Affiliated Hospital of Nantong University; Level of the institution：, None | esophageal squamous carcinoma | | | | |
NCT06039891: Nimotuzumab Plus Tislelizumab for Recurrent and Metastatic Cervical Cancer |
|
|
| Not yet recruiting | 2 | 55 | NA | Nimotuzumab、Tislelizumab, Nimotuzumab, Tislelizumab plus radiotherapy | Peking Union Medical College Hospital | Cervical Cancer | 10/24 | 10/27 | | |
ChiCTR2300068872: Clinical study of rre-combined nimouzumab for reversing drug resistance in hepatocellular carcinoma after failure of treatment of 1-L lenalutinib-containing regimen |
|
|
| Recruiting | 2 | 37 | | nimotuzumab，400mg，D1,8,15,28d/cycle | The Third Affiliated Hospital of Navy Military Medical University (Shanghai Eastern Hepatobiliary Surgery Hospital); The Third Affiliated Hospital of Navy Military Medical University (Shanghai Eastern Hepatobiliary Hospital), Self-financing | hepatocelluar carcinoma | | | | |
NCT05316480: Nimotuzumab in EGFR Highly Expressed Pancreatic Neuroendocrine Neoplasms |
|
|
| Not yet recruiting | 2 | 42 | RoW | Nimotuzumab | Fudan University | Pancreatic Neuroendocrine Neoplasm | 04/25 | 12/26 | | |
ChiCTR2000034375: TIP (paclitaxel + ifosfamide + cisplatin) Combined with Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer |
|
|
| Not yet recruiting | 2 | 29 | | TIP (paclitaxel + ifosfamide + cisplatin)+Nimotuzumab+Triprilimab | Sun Yat-sen University Cancer Center; Sun Yat-sen University Cancer Center, Self-financing | Penile Caner | | | | |
NCT05024019: Nimotuzumab Combined With Radiotherapy in High-risk Patients With HNSCC Not Suitable for Cisplatin After Surgery |
|
|
| Not yet recruiting | 2 | 95 | RoW | Nimotuzumab | Eye & ENT Hospital of Fudan University | Head and Neck Squamous Cell Carcinoma | 08/25 | 08/25 | | |
ChiCTR2100054151: Clinical study of neoadjuvant chemoradiation combined with Nimotuzumab and Camrelizumab in the treatment of resectable/potentially resectable locally advanced esophageal cancer |
|
|
| Not yet recruiting | 2 | 57 | | Camrelizumab + Nimotuzumab + Carboplatin + Albumin Paclitaxel + radiotherapy + surgery | The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital); The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Jiangsu Hengrui Pharmaceutical Co., Ltd.; Baitai Biological Pharmaceutical Co., Ltd. | Esophageal Squamous Cell Carcinoma | | | | |
ChiCTR2000041139: An open-label, single-arm phase II clinical study of nimotuzumab concurrently with induction chemotherapy and sequential nimotuzumab combined with radiotherapy or concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma |
|
|
| Recruiting | 2 | 76 | | Nimotuzumab plus induction chemotherapy,sequential nimotuzumab plus radiotherapy or nimotuzumab combined with concurrent chemoradiotherapy | The second affiliated hospital of Nanchang University; The Second Affiliated Hospital of Nanchang University, Self-financing | Nasopharyngeal carcinoma | | | | |
ChiCTR2200064587: Docetaxel and cisplatin induction chemotherapy combined with nimotuzumab and penpulimab followed by concurrent chemoradiotherapy in patients with advanced head and neck cancer: A phase II singel arm trial |
|
|
| Not yet recruiting | 2 | 48 | | Docetaxel and cisplatin induction chemotherapy combined with nimotuzumab and penpulimab followed by concurrent chemoradiotherapy | Xijing Hospital; Xijing Hospital, clinical trials project of the air force medical university | head neck cancer | | | | |
ChiCTR2300073467: PD-1 inhibitor combined with nimotuzumab and gemcitabine plus cisplatin for the first-line treatment of newly diagnosed metastatic nasopharyngeal carcinoma: a single arm, phase II clinical study |
|
|
| Recruiting | 2 | 26 | China | The first stage is the PD-1 inhibitor plus nimotuzumab and chemotherapy combination treatment, 21 days is a cycle, a total of 4-6 cycles, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion, day 0 (one day before chemotherapy); Nimotuzumab, intravenous infusion, on day 0 (one day before chemotherapy); Chemotherapy: Gemcitabine, intravenous infusion, day 1 and 8, (1000mg/m2), Cisplatin, intravenous infusion, day 1 (80mg/ m2). The second stage is the maintenance treatment, and the specific discription is: PD-1 inhibitor (selected by the researchers, including but not limited to Camrelizumab, Toripalimab, Tislelizumab, Sintilimab, etc.), intravenous infusion (day 1, every 3 weeks); Capecitabine (650mg/m2, take orally, two times every day); PD-1 inhibitor and Capecitabine should be administered until the end of the study. | Dongguan People's Hospital ; Dongguan People's Hospital, Biotech Pharmaceutical Co., Ltd | nasopharyngeal carcinoma | | | | |
ChiCTR2300072843: Prospective study of nituzumab combined with gemcitabine and albumin paclitaxel in first-line treatment of advanced pancreatic cancer |
|
|
| Recruiting | 2 | 31 | | nituzumab combined with gemcitabine and albumin paclitaxel | Shenzhen Second People's Hospital; Shenzhen Second People's Hospital, Own in-hospital support | pancreatic cancer | | | | |
ChiCTR2200063496: A prospective, single arm, phase II study of neoadjuvant treatment of resectable head and neck tumors with nituzumab combined with epimumab |
|
|
| Not yet recruiting | 2 | 51 | | Nytuzumab was combined with ipilimumab ;Nytuzumab was combined with ipilimumab | Tianjin Medical University General Hospital; Tianjin Medical University General Hospital, Clinical medicine research project of Tianjin Medical University General Hospital | Head and neck squamous cell carcinoma | | | | |
ChiCTR2200057917: Phase II clinical study of nituzumab combined with first-line chemotherapy in the treatment of advanced esophageal squamous cell carcinom |
|
|
| Not yet recruiting | 2 | 60 | | Nituzumab combined with chemotherapy | Cancer Hospital Affiliated to Harbin Medical University; Cancer Hospital Affiliated to Harbin Medical University, enterprise sponsor | esophagus cancer | | | | |
ChiCTR2200060136: Nituzumab plus terriprizumab combined with GP versus nituzumab combined with GP in patients with high-risk locally advanced nasopharyngeal carcinoma: a multicenter, randomized controlled, open clinical study |
|
|
| Recruiting | 2 | 292 | China | Induction chemotherapy with teriprizumab plus nituzumab and GP followed by radical radiotherapy ;Induction chemotherapy with nituzumab and GP followed by chemoradiotherapy | Sun Yat-sen University Cancer Center ; Sun Yat-sen University Cancer Center, NA | nasopharyngeal carcinoma | | | | |
ChiCTR-ONC-14004561: A phase II, open and multi center study of nimotuzumab concurrent with intensity modulated radiation therapy in recurrent nasopharyngeal carcinoma |
|
|
| Completed | 1/2 | 67 | | nimotuzumab concurrent with intensity modulated radiation therapy | Fujian Provincial Cancer Hospital; Level of the institution：, Baitai biological pharmaceutical co., LTD | nasopharyngeal carcinoma | | | | |
ChiCTR-TRC-14004997: A Prospective, Multicenter, Randomized, Controlled, Phase II Study of High-dose Nimotuzumab in Combined with Chemoradiotherapy Compared with Chemoradiotherapy alone for Local Advanced Esophageal Cancer |
|
|
| Recruiting | 1/2 | 120 | | Nimotuzumab in Combined with Chemoradiotherapy ;Chemoradiotherapy | Fujian Provincial Cancer Hospital; Level of the institution：, Biotechplc Pharmaceutical CO., LTD | Local Advanced Esophageal Cancer | | | | |
NCT02947386: Nimotuzumab and Nivolumab in Treating Patients With Advanced Non-small Cell Lung Cancer |
|
|
| Completed | 1/2 | 7 | US | Laboratory Biomarker Analysis, Nimotuzumab, Thera-CIM-hr3, TheraCim hR3, Theraloc, Nivolumab, BMS-936558, MDX-1106, NIVO, ONO-4538, Opdivo | Roswell Park Cancer Institute | EGFR Gene Mutation, Recurrent Non-Small Cell Lung Carcinoma, Stage IIIA Non-Small Cell Lung Cancer, Stage IIIB Non-Small Cell Lung Cancer, Stage IV Non-Small Cell Lung Cancer | 04/21 | 09/22 | | |
NCT04235114: Evaluation of 89Zr-DFO-nimotuzumab for Non-invasive Imaging of EGFR+ Cancers by Positron Emission Tomography (PET) |
|
|
| Recruiting | 1/2 | 14 | Canada | 50 mg 89Zr-DFO-Nimotuzumab, 1 mg 89Zr-DFO-Nimotuzumab | University of Saskatchewan | Lung Cancer, Colorectal Cancer | 09/26 | 12/26 | | |
ChiCTR2100049286: Single arm clinical study of carbon ion radiotherapy combined with nituzumab and gemcitabine in the treatment of pancreatic cancer |
|
|
| Not yet recruiting | 1/2 | 69 | | Targeted therapy + chemotherapy + carbon ion beam radiation therapy | Wuwei Tumor Hospital Heavy Ion Center; Wuwei Tumor Hospital Heavy Ion Center, Wuwei Heavy Ion Center Construction Project | Pancreatic cancer | | | | |
NCT04459065: Evaluation of IRDye800CW-nimotuzumab in Lung Cancer Surgery |
|
|
| Recruiting | 1/2 | 36 | Canada | IRDye800CW-nimotuzumab | University of Saskatchewan, Western Economic Diversification Canada | Lung Cancer | 09/26 | 10/26 | | |
NCT05355168: Neoadjuvant Chemoradiotherapy Combined With Camrelizumab and Nimotuzumab for Esophageal Squamous Cell Carcinoma |
|
|
| Recruiting | 1/2 | 57 | RoW | neoadjuvant chemoradiotherapy combined with Camrelizumab and Nimotuzumab followed by surgery | Anhui Provincial Hospital | Toxicity, Drug | 11/25 | 12/25 | | |
